Related Videos
Video
ASCO26: Atish Choudhury, MD, PhD, A-DREAM/Alliance A032101
A-DREAM/Alliance A032101 study presented by Dana-Farber Cancer Institute's Dr. Atish Choudhury shows 41% of favorable responders to testosterone suppression plus androgen receptor pathway inhibitor remaining treatment-free with testosterone ...
Video
Prostate Cancer Highlights from ASCO 2025
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from ASCO 2025.
Video
Talazoparib + Tazemetostat Presented by Atish Choudhury, MD, PhD.
Dr. Atish Choudhury presented clinical trial results evaluating the combination of talazoparib and tazemetostat in advanced prostate cancer.
Video
Prostate Cancer Conference Highlights from ASCO GU 2024
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from ASCO GU 2024.